Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ipsen S.A. ADR (IPSEY)

Ipsen S.A. ADR (IPSEY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 7,479,651
  • Shares Outstanding, K 335,260
  • Annual Sales, $ 3,548 M
  • Annual Income, $ 764,990 K
  • 60-Month Beta 1.04
  • Price/Sales N/A
  • Price/Cash Flow 6.08
  • Price/Book 2.20
Trade IPSEY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/10/22
  • Annual Dividend & Yield 0.24 (1.12%)
  • Most Recent Dividend 0.238 on 05/31/22
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.3500 +8.38%
on 09/28/22
26.0500 -11.17%
on 09/13/22
-0.1300 (-0.56%)
since 08/30/22
3-Month
21.3500 +8.38%
on 09/28/22
26.0800 -11.27%
on 08/10/22
+0.1500 (+0.65%)
since 06/30/22
52-Week
21.1700 +9.31%
on 06/16/22
32.5100 -28.82%
on 04/05/22
-1.0100 (-4.18%)
since 09/29/21

Most Recent Stories

More News
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology

Regulatory News:

OTC.VN : 0.500 (unch)
IPN : 34.71 (-0.54%)
IPSEY : 23.1400 (+3.72%)
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y

Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.

NVAX : 18.20 (-1.99%)
EPZM : 1.4700 (-1.34%)
IPSEY : 23.1400 (+3.72%)
SESN : 0.4250 (+9.17%)
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022

Regulatory News:

OTC.VN : 0.500 (unch)
EPZM : 1.4700 (-1.34%)
IPN : 34.71 (-0.54%)
IPSEY : 23.1400 (+3.72%)
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

Regulatory News:

OTC.VN : 0.500 (unch)
IPN : 34.71 (-0.54%)
IPSEY : 23.1400 (+3.72%)
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic

Regulatory News:

OTC.VN : 0.500 (unch)
IPN : 34.71 (-0.54%)
IPSEY : 23.1400 (+3.72%)
Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance

Regulatory News:

OTC.VN : 0.500 (unch)
IPN : 34.71 (-0.54%)
IPSEY : 23.1400 (+3.72%)
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Epizyme, Inc. (NasdaqGS: EPZM) to Ipsen S.A....

EPZM : 1.4700 (-1.34%)
IPSEY : 23.1400 (+3.72%)
5 Buy-Rated Healthcare Stocks Trading at a Discount

Inelastic demand, growing investments, and impressive breakthroughs should help the healthcare sector survive the potential recession. This is why we believe quality healthcare stocks Assertio (ASRT),...

ASRT : 2.27 (+4.61%)
BAYRY : 11.5600 (-1.37%)
BMY : 71.09 (-0.86%)
CPRX : 12.83 (+1.02%)
IPSEY : 23.1400 (+3.72%)
4 Mid-Cap Stocks That are Still Cheap

High inflation pressure, the Fed’s interest rate hikes, and prospects of a recession are weighing heavily on the market sentiment lately. As these factors are likely to persist for quite some time, prominent...

AN : 101.87 (+1.09%)
IPSEY : 23.1400 (+3.72%)
KT : 12.22 (unch)
MTLHY : 23.4000 (-0.93%)
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More

Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.

GILD : 61.69 (-2.19%)
EPZM : 1.4700 (-1.34%)
IPSEY : 23.1400 (+3.72%)
KZR : 8.61 (-0.12%)
STRO : 5.55 (+2.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 23.1400
2nd Resistance Point 23.1400
1st Resistance Point 23.1400
Last Price 23.1400
1st Support Level 23.1400
2nd Support Level 23.1400
3rd Support Level 23.1400

See More

52-Week High 32.5100
Fibonacci 61.8% 28.1781
Fibonacci 50% 26.8400
Fibonacci 38.2% 25.5019
Last Price 23.1400
52-Week Low 21.1700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar